ALGS
Aligos Therapeutics Inc (ALGS)
Healthcare • NASDAQ • $6.67+3.57%
- Symbol
- ALGS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.67
- Daily Change
- +3.57%
- Market Cap
- $43.03M
- Trailing P/E
- N/A
- Forward P/E
- -1.36
- 52W High
- $13.69
- 52W Low
- $3.98
- Analyst Target
- $56.29
- Dividend Yield
- N/A
- Beta
- 2.28
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc.…
Company websiteResearch ALGS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.